BioMarin Pharma (BMRN) Tops Q2 EPS by 8c, Affirms FY Revenue Guidance, Lowers R&D Expense Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $126 at SunTrust Robinson Humphrey
August 3, 2018 2:32 PM EDTSunTrust Robinson Humphrey raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $126.00 (from $121.00) while maintaining a Buy rating.
Analyst Edward Nash commented, "BioMarin reported a strong 2nd quarter. All but Kuvan's net product sales beat Street consensus. Prior guidance... More
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $109 at Stifel
August 3, 2018 9:36 AM EDTStifel raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $109.00 (from $102.00) while maintaining a Buy rating.
... MoreBioMarin Pharmaceutical Inc. (BMRN) PT Raised to $98 at Barclays
August 3, 2018 5:06 AM EDTBarclays raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $98.00 (from $95.00) while maintaining a Equalweight rating.
... More